
UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum
UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Clinic - Promising Early Data Supports Phase II Trial PORTLAND, OR, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- UbiVac, www.ubivac.com, a private, …